Eli Lilly & Co. is looking to increase the pace of business development to build out its portfolio, Chief Scientific Officer Dan Skovronsky said during an investor briefing in New York Dec. 19. Skovronsky oversees business development since taking over as chief scientific officer and president of Lilly Research Labs in June, and he said there have been some changes to the company's business development strategy.
"Some of the changes that you've probably seen already [are] … just a higher pace of deals overall," he said. "We feel a greater sense of urgency
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
